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Abstract
Background: Endothelial injury is an early and enduring feature of cardiovascular disease. Inflammation and
hypoxia may be responsible for this, and are often associated with the up-regulation of several transcriptional
factors that include Hypoxia Inducible Factor-1 (HIF-1). Although it has been reported that HIF-1α is detectable in
plasma, it is known to be unstable. Our aim was to optimize an assay for HIF-1α to be applied to in vitro and in
vivo applications, and to use this assay to assess the release kinetics of HIF-1α following endothelial injury.
Methods: An ELISA for the measurement of HIF-1α in cell-culture medium and plasma was optimized, and the
assay was used to determine the best conditions for sample collection and storage. The results of the ELISA were
validated using Western blotting and immunohistochemistry (IHC). In vitro, a standardized injury was produced in
a monolayer of rat aortic endothelial cells (RAECs) and intracellular HIF-1α was measured at intervals over 24 h. In
vivo, a rat angioplasty model was used. The right carotid artery was injured using a 2F Fogarty balloon catheter.
HIF-1α was measured in the plasma and in the arterial tissue (0, 1, 2, 3 and 5 days post injury).
Results: The HIF-1α ELISA had a limit of detection of 2.7 pg/mL and was linear up to 1000 pg/ mL. Between and
within-assay, the coefficient of variation values were less than 15%. HIF-1α was unstable in cell lysates and
plasma, and it was necessary to add a protease inhibitor immediately after collection, and to store samples at
-80 °C prior to analysis. The dynamics of HIF-1α release were different for the in vitro and in vivo models. In vitro,
HIF-1α reached maximum concentrations approximately 2 h post injury, whereas peak values in plasma and
tissues occurred approximately 2 days post injury, in the balloon injury model.
Conclusion: HIF-1α can be measured in plasma, but this requires careful sample collection and storage. The
carotid artery balloon injury model is associated with the transient release of HIF-1α into the circulation that
probably reflects the hypoxia induced in the artery wall.
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Background
Endothelial injury is an early and enduring feature of
cardiovascular disease. Inflammation and hypoxia may
be partially responsible for this, and are often associ-
ated with the up regulation of transcriptional factors
that include hypoxia-inducible factor-1 (HIF-1) (Ferns
and Heikal 2017).
HIF-1 is a hetero-dimeric transcription factor that
consists of an oxygen-regulated α- subunit and a consti-
tutively expressed ß-subunit (Chu and Jones 2016). HIF-
1β is expressed in the nucleus and its activity is un-
affected by hypoxia, whereas the HIF-1α subunit has a
short half-life (5 min) and its stability is regulated by
oxygen tension (Gao et al. 2012). Intracellular HIF-1α is
unstable under normoxic conditions, being rapidly de-
graded by prolyl hydroxylase enzymes (Semenza 2014).
These enzymes are inactivated under low oxygen levels,
explaining why HIF-1α is induced by hypoxia. Some
small molecules such as dimethyloxalylglycine (DMOG)
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can stabilize HIF levels under normoxic conditions by
inhibiting prolyl hydroxylase (Zhang et al. 2016). Three
distinct HIF-α subunits have been identified (HIF-1α,
HIF-2α and HIF-3α) that have a tissue-specific pattern
of expression (Al Okail 2010). HIF-1α and HIF 2α are
similar but not identical. HIF-1α is expressed in re-
sponse to acute hypoxia, whilst HIF-2α is related to
chronic responses (Loboda et al. 2012). HIF-1 drives vas-
cular endothelial growth factor (VEGF) expression and
angiogenesis while HIF-2 production blocks angiogen-
esis by inducing the expression of the soluble VEGF
receptor-1, sequestering biologically active, free VEGF. It
is possible that HIF-2α evolved to regulate the VEGF re-
sponse to hypoxia and the resultant development of the
vascular network (Eubank and Marsh 2011; Eubank et
al. 2011; Loboda et al. 2012). Therefore, HIF-1 is a key
transcription factor in the adaptive responses to low oxygen
(Lambert et al. 2010). HIF-1 is involved in the cellu-
lar adaptation to injury, inflammation, infection and
cancer (Eubank and Marsh 2011). HIF is also induced
by inflammatory cytokines including tumour necrosis
factor alpha (TNF-α) and interleukin-1β (IL-1β), that
increase the accumulation and transcriptional activity
of HIF-1α (Gao et al. 2012).
HIF-1 also regulates a variety of other important cellular
responses affecting a spectrum of protective/reparative
processes including angiogenesis, cell proliferation and
survival (Ferns and Heikal 2017; Lambert et al. 2010). It
promotes the transcription of more than 100 target genes
including several angiogenic factors, apart from VEGF, ni-
tric oxide synthase (the inducible and the endothelial
forms), platelet-derived growth factor, and erythropoietin
(EPO) (Gao et al. 2012; Natarajan et al. 2007).
Several semi-quantitative methods have been used to
estimate HIF-1α levels, for example Western blotting
and immunocytochemistry (Karshovska et al. 2007; Sri-
nivasan and Dunn 2011). HIF-1α levels have also been
assessed indirectly by quantifying mRNA expression, or
by measuring downstream target genes such as VEGF
and EPO (Formento et al. 2005; Park et al. 2014).
Due to the need for a more precise method for HIF-1α
quantification in biological samples, some quantitative
methods have also been developed, that include the en-
zyme linked immunosorbent assay (ELISA) (Formento et
al. 2005). Although it has been reported that HIF-1α is
detectable in plasma, (He et al. 2016a) it is unstable and
is rapidly degraded under normal oxygen tensions, as
discussed above (Park et al. 2014). As a transcription fac-
tor, it is normally located within the cell, and there has
also been some doubt about its release into plasma
(Ferns and Heikal 2017).
Plasma HIF-1α may potentially represent a biomarker
of vascular wall hypoxia, or the extent of atherosclerosis.
It may also reflect the severity of hypoxia associated with
other pathological conditions including some tumours.
Hence, there are a number of possible clinical applica-
tions for a plasma HIF-1α assay.
Our aim was to optimize an assay for HIF-1α to be ap-
plied to in vitro and in vivo studies, and to establish the
conditions for sample collection and storage. We then
aimed to use the assay to assess the release kinetics of
HIF-1α following endothelial injury in vitro and in vivo.
Methods
All chemicals were from Sigma Aldrich (Dorset, UK),
unless otherwise stated.
Cell culture
Rat aortic endothelial cells (RAECs) were isolated from
the aortae of Sprague Dawley rats (male, 2 weeks old) and
used between passages 2–5 (Kobayashi et al. 2005). The
cells were cultured in Endothelial cell growth medium
supplemented with 10% fetal bovine serum (FBS) and
Penicillin/Streptomycin (final concentration 100 IU/mL),
and were cultured, prior to our experiments, at 37 °C in a
humidified atmosphere containing 5% CO2 and 21% O2.
When indicated, experiments under hypoxic conditions
were performed under 1% O2, 5% CO2 and 94% N2.
Effect of storage on the HIF-1α stability
Storage time and temperature, and the effects of adding
protease inhibitors to the experimental samples were in-
vestigated to determine the optimum storage conditions
for HIF-1α measurements.
For the effect of temperature, aliquots of samples were
taken and maintained at different temperatures (− 80, −
20, 4 and 37 °C). HIF-1α concentrations were determined
after 24 h storage using the ELISA as described below.
To determine the effect of storage duration on HIF-1α
concentrations, fresh samples were divided into 3 aliquots,
and HIF-1α was measured immediately, or after 1 and
2 weeks. Aliquots were stored at -80 °C until analysis.
To assess the requirement for the addition of a prote-
ase inhibitor, aliquots from a set of fresh samples were
treated with the protease inhibitor, aprotinin (300 nM)
(Mosher et al. 2014). These samples were stored for 1 or
2 weeks at -80 °C until they were analyzed.
Linearity, limit of detection and limit of quantification
of the assay were determined. Assay precision was
assessed by measuring intra and inter-plate replicates
with appropriate samples and HIF-1α standards.
Quantification of HIF-1α after administration of a HIF-1α
inducer
Cells were seeded into 24 well plates with a seeding
density of 1 × 105 cell/mL and cultured until 80%
confluent. The HIF-1α inducer; DMOG was added at
different concentrations ranging from 0 to 500 μM and
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incubated for 24 h at 21% O2. Cells incubated in hypoxic
conditions (1%O2) were used as a positive control for
HIF-1α induction. Cells were then lysed and HIF-1α was
measured using the ELISA method. In another set of ex-
periments, cells were similarly treated with different
concentrations of DMOG, lysed, and the down-stream
effector, VEGF gene expression was measured.
Scratch assay in vitro injury model
The “scratch assay” is a model of cell/ wound injury, and
has been described previously (Heikal et al. 2015).
Briefly, a reproducible scratch was produced in the
endothelial monolayer, and the cells were then incubated
in room air (21% O2) in a 5% CO2 incubator. Cells were
then lysed and intracellular HIF-1α assessed. This was
evaluated over a period of 24 h using the ELISA.
Animal studies
Male Sprague Dawley rats (450 g) were used. All animal
experiments were performed under UK Home Office ap-
proval according to the Animals Scientific Procedures
Act, 1986 and subsequent revisions, and conformed to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the National Institutes of Health (NIH Publica-
tion No. 85–23, revised 1996). Studies were designed and
conducted in accordance with the ARRIVE guidelines
(Kilkenny et al. 2010). Rats were acclimatized in home
cages for 1 week prior to experimentation with ad libitum
access to food and water and on a 12h light-dark cycle.
Quantification of HIF-1α post DMOG administration
Rats were anesthetized using 2% isoflurane and placed in
a supine position. The right carotid artery was exposed
and DMOG was applied locally at different concentra-
tions (0–7.5 mg/Kg) on the artery using pluronic gel as
the vehicle (30%w/w). Three rats were used for each
concentration of DMOG. After 24 h, blood was collected
from a tail vein, and HIF-1α was measured by ELISA.
Treated animals were culled after 24 h and both the
right (treated) and left (untreated) carotid arteries were
isolated and snap frozen for PCR analysis.
Angioplasty in vivo injury model
Injury was induced in the rat’s carotid artery using a balloon
catheter (for angioplasty) as previously described (Tulis
2007). Briefly, rats (450 g) were anesthetized using 2% iso-
flurane and placed in a supine position. The right carotid
artery was exposed and a 2F Fogarty catheter was used to
cause injury. The catheter was inserted into the common
carotid artery via the external carotid to cause complete re-
moval of the vascular endothelium from the common ca-
rotid artery down to its junction with the aortic arch.
Blood was collected from a tail vein at 0, 1, 2 and
5 days after injury into EDTA containing sample tubes.
Plasma was separated and used for the measurement of
HIF-1α using ELISA.
At the end of the experiment, rats were culled. Both
the right (treated) and left (untreated) carotid arteries
were isolated and snap frozen for PCR analysis.
In another set of experiments culled animals were per-
fused fixed with PBS followed by 4% paraformaldehyde.
Both the right (treated) and left (untreated) carotid arter-
ies were isolated and kept in 4% paraformaldehyde at
room temperature for 1 h. Fixed arteries were then placed
in a 30% sucrose solution and left overnight after which
they were snap frozen in OCT blocks for cryo-sectioning.
HIF-1α enzyme linked immunosorbent assay (ELISA)
HIF-1α was measured using a commercial ELISA kit
(R&D systems/ Biotechne, UK) following the manufac-
turers’ instructions.
a. Standard calibration curves were obtained using
HIF-1α protein standards, allowing the limit of de-
tection, limit of quantification and coefficient of
variation to be determined.
b. In vitro samples: Endothelial cells were lysed in
80 μL lysis buffer (25 mmol/L Tris HCl pH 7. 6,
0.1% SDS, 1% deoxycholate, 1% NP40, 0.5 mol/L
EDTA, 40 mmol/L EGTA and protease inhibitors).
Lysates were then centrifuged at 11000 g for 15 min
at 4 °C and the supernatant was collected. Protein
concentrations were quantified using a BCA reagent
kit (Pierce Biotechnology). Results were expressed
as pg/ mg protein.
c. Rat plasma: Blood was collected from the tail vein
of each animal and placed into tubes containing
EDTA as an anti-coagulant. Blood was kept on ice
and centrifuged to separate the plasma, to which a
protease inhibitor was immediately added. HIF-1
was then quantified.
Real time qPCR
The gene expression of vascular endothelial growth factor
(VEGF was analysed by quantitative PCR (qPCR). Cells
were lysed using TRIzol (Invitrogen, Life Technologies)
and RNA was then extracted and purified. RNA quality
and concentration were determined using a NanoDrop
ND-1000 (NanoDrop Technologies). Reverse transcription
and real-time quantitative PCR (qPCR) were carried out
on RNA samples for VEGF and β2-microglobulin (a
housekeeping gene not affected by changes in oxygen
levels), using TaqMan gene expression assays (Applied
Biosystems/Life Technologies). For gene expression quan-
tification, the comparative threshold cycle (ΔΔCt) method
was used following the manufacturer’s instructions. Re-
sults were normalized to β2-microglobulin expression and
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expressed as arbitrary units using one of the normoxic un-
treated samples as a calibrator.
For the analysis of rat tissue, RNA was extracted and
purified from the frozen artery sections using TRIzol
(Invitrogen, Life Technologies). RNA quality and con-
centrations were determined using a NanoDrop ND-
1000 (NanoDrop Technologies). Reverse transcription
and real-time quantitative PCR (qPCR) were carried out
on RNA samples for VEGF and β2-microglobulin as de-
scribed earlier.
Western blotting
Western blotting was used to verify the presence of HIF-
1α in some samples. Cells were lysed and the protein
content of the lysate quantified as previously described
(Heikal et al. 2015). Thirty μg of cellular proteins were
separated on a 10% SDS-polyacrylamide gel electrophor-
esis and transferred onto a nitrocellulose membrane
(Amersham/ GE Healthcare Life Sciences, Little Chal-
font, Buckinghamshire, UK). After blocking with 5%
skimmed milk (for HIF-1α detection) or 5% bovine
serum albumin; BSA (for GAPDH detection) for 1 h,
membranes were incubated with the appropriate primary
antibody overnight, followed by HRP-conjugated sec-
ondary antibodies for 1 h at room temperature. HIF-1α
and GAPDH (loading control) were detected using
rabbit anti-HIF-1α (NB100-479, Novus biologicals, UK)
and rabbit anti-GAPDH (14C10, Cell Signaling Technol-
ogy, UK) at 1:500 and 1:1000 respectively and an anti-
rabbit secondary antibody (A0545, Sigma Aldrich, UK)
at 1:20,000 dilution. Protein bands were visualized by ex-
posing membranes developed with the ECL reagent
(Amersham/ GE Healthcare Life Sciences) to chemilu-
minescence film (Hyperfilm ECL, Amersham/ GE
Healthcare Life Sciences). Bands were quantified using
Image J software.
Immunohistochemistry
Snap frozen carotid arteries were embedded in OCT and
were cryo-sectioned (5 μm in thickness) and sections
placed onto silane-coated slides. Sections were then
washed with PBS and blocked using 10% donkey serum
and 0.3% Triton X-100 for 1 h a room temperature, they
were incubated with mouse anti-HIF-1α at 1:50 dilution
in 1% donkey serum at 4 °C overnight. Donkey anti-
mouse IgG-FITC (sc-2099, Santa Cruz Biotechnology,
Germany) (1:100 dilution each) was the secondary anti-
bodies used to detect HIF-1 (green stain). For comparing
HIF-1α expression in different sections, instrument
(fluorescence microscope) settings were kept constant
for all sections using uninjured arteries as the control. In
another set of experiments, cryo-sliced carotid artery
sections were used to visualize endothelial cells (ECs)
and smooth muscle cells post injury. Arteries were
stained with rabbit anti-CD31 (NB100-2284, Novus bi-
ologicals, UK) at 1:50 dilution and mouse anti-alpha
smooth muscle actin at 1:50 dilution (NB2-33006,
Novus biologicals, UK) followed by Alexafluor 647 con-
jugated anti-rabbit secondary antibody (red stain) and
FITC-conjugated anti-mouse secondary antibody (green
stain) respectively at 1:200 dilution each. Cellular nuclei
were stained with Prolong® Gold anti-fade reagent
with DAPI (P36941, Life technologies, UK). Images
were obtained using a fluorescence microscope (Leica
CTR 5000).
Statistical analysis
All data were analyzed using Graph Pad Prism 4 software.
Differences in treatment were tested for significance
using one-way analysis of variance (ANOVA) followed
by a Bonferroni correction for multiple comparisons
post-hoc test.
Fig. 1 Calibration curve for standard HIF-1α αprotein at concentration range (0–500 ng/mL) using ELISA assay for protein quantification. The calibration
curve was used to determine linearity, the limit of detection and quantification as well as inter and intra variability of the assay. Each point represents
the mean ± SEM of 6 independent experiments
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Results
Reliability of the ELISA assay for the quantification of HIF-
1α in biological samples
Figure 1 shows the results of a typical standard curve
using standard recombinant HIF-1α. The assay was lin-
ear between 0 and 1000 pg/ mL (r = 0.99). The method
was sensitive, with a detection limit of 2.7 pg/ mL. The
ELISA had an intra and inter-assay coefficient of vari-
ation of < 15% and an accuracy of 99.4% ± 8.3%.
The results of the HIF-1α measurement using the ELISA
assay were compared with the findings using the conven-
tional semi-quantitative assay; Western blot. The Western
blot in Fig. 2a shows a specific band for the recombinant
HIF-1α standard protein at a molecular weight of approxi-
mately130 kDa with a band intensity that was concentra-
tion dependent and detectable in the range used (6–
200 ng/mL). When cell lysates were analyzed by Western
blot, we could detect a specific band for HIF-1α at the
molecular weight of 130 kDa in addition to a faint degrad-
ation band at 80 kDa. (Lidgren et al. 2005; Srinivasan and
Dunn 2011) A stronger signal of the higher molecular
weight band was detected in cells cultured for 24 in hyp-
oxia. GAPDH was used as a loading control showing a
band in each cell lysate at molecular weight 40 kDa.
Temperature, storage time and presence of protease
inhibitors are critical for the stability of HIF-1α
Figure 3a shows the detection of HIF-1α by ELISA in cell
lysates kept for 24 h at different temperatures. Storage at
-80 °C appears essential for the optimal preservation of
the protein. In the experiment shown in Fig. 3b, samples
were kept at -80 °C for prolonged periods of time, with
and without aprotinin. It is very clear that a protease in-
hibitor is essential for preventing the degradation of HIF-
1α in the stored samples. Other protease inhibitors such
as Complete Mini protease inhibitor cocktail (Roche) were
tested and showed similar protection against HIF-1α deg-
radation (data not shown).
Measurement of HIF-1α in cell lysates and plasma samples
HIF-1α was detected in cell lysates treated with
DMOG. HIF-1α was measured in cell lysates using the
optimized sample collection discussed in the previous
section. HIF-1α was induced using DMOG. DMOG
caused a significant increase HIF-1α levels when incu-
bated with RAECs for 2 h at a concentration of 100 μM
(Fig. 4a) and resulted in transcriptional activation of
HIF-1α target genes, increasing the expression of VEGF
gene 3–4 fold (Fig. 4b).
HIF-1α is increased in cell lysate in an in vitro injury model
The kinetics of HIF-1α release was investigated in the
scratch assay model. HIF-1α concentrations in the lysate
reached a maximum at approximately 2 h post injury,
after which they gradually returned to baseline (Fig. 5a).
This pattern of HIF-1α levels was mirrored by changes
in VEGF gene expression (Fig. 5b).
Circulating HIF-1α in rats treated with DMOG
HIF-1α was increased in plasma after treatment of the ca-
rotid artery with DMOG applied locally at a concentration
ranging from 0 and 7.5 mg/Kg in a dose-dependent fash-
ion (Fig. 6a). VEGF gene expression in the treated carotid
arteries was consistent with the increased levels of plasma
HIF-1α following DMOG administration, but there was
no increase in the contralateral, untreated artery (Fig. 6b).
Circulating HIF-1α after in vivo arterial injury
The kinetics of HIF-1α release was then measured in a
rat model of carotid angiolplasty, using the optimised
conditions for plasma sample collection and storage,
prior to analysis using the ELISA method. HIF-1α re-
lease reached a maximum at approximately 2 days after
injury, and then fell over the next 5 days, but remained
above baseline (Fig. 7a). In a separate experiment, we
looked at the effect of adding proteinase inhibitors to
the blood immediately after collection before plasma
Fig. 2 Western blot analysis of HIF-1α. a Different concentrations of HIF-1α standard protein and b cell lysates from the cells cultured in 21% or
1% O2. HIF-1α standards and in cell lysates showed a band at a molecular weight of approximately 130 kDa. GAPDH (loading control) showed a
band at a molecular weight of approximately 36 kDa. Numbers on the left indicate the migration of molecular weight standards
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separation. This has been done by spiking the blood with
HIF-1α protein (0.6 ng/mL). Blood samples were then
split where protease inhibitor was added to one group
after which plasma was separated. In the other group,
plasma was separated first prior to the addition of prote-
ase inhibitor. Samples were then stored for 48 h prior to
analysis. This showed that there was no significant dif-
ference between adding the protease inhibitor to the
blood immediately after collection or to the plasma after
separation and found that this was equally effective.
Blood samples were kept on ice after collection and
plasma was separated rapidly. Although adding the in-
hibitor immediately to the blood rather than after
plasma separation did not increase the recovery of HIF-
1α further (See Additional file 1), this may be more prac-
tical in a clinical setting.An increase in local VEGF gene
expression in the carotid artery was only observed in
injured arteries reaching a maximum level at 2 days after
injury, consistent with changes in plasma HIF-1α, and
falling to baseline by the fifth day after injury. Uninjured
contralateral arteries from the same rats showed no
change in VEGF gene expression (Fig. 7b).
HIF-1α localization
Tissue HIF-1α levels were also assessed in the injured
carotid arteries using immunohistochemistry. An in-
crease was observed in the smooth muscle cells that was
maximal 2 days after injury (Fig. 8c) and still detectable
at 5 days (Fig. 8d). HIF-1α was co-localised in the
smooth muscle cells after injury.
Discussion
A reliable and sensitive HIF-1α ELISA was established
and used to assess the stability of HIF-1α in plasma and
Fig. 4 Concentration response curve showing (a) HIF-1α levels and (b) fold change in VEGF gene expression in cell lysates after treating rat aortic
endothelial cells with different concentrations of DMOG (0–500 uM). Cells incubated at 21% O2 were used as the untreated control group and
cells incubated at 1% O2 were used as a positive control for HIF-1α induction. The data are mean ± SEM of 6 independent experiments (triplicates
in each experiment) where * P < 0.05, **P < 0.01 and ***P < 0.001
Fig. 3 Effect of (a) temperature, (b) storage time and presence of a protease inhibitor (aprotinin) on the degradation of HIF-1α in cell lysates. The
data are mean ± SEM of 3 independent experiments (triplicates in each experiment), *P<0.05, **P < 0.01 and ***P < 0.001 compared with freshly
collected samples by ANOVA
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tissue culture medium. Samples could be stored for sev-
eral days at -80 °C but required the addition of aprotinin.
HIF-1α was released following endothelial injury in vitro
and in vivo, in the balloon injury model in the rat.
Hypoxia has important effects on intermediary metab-
olism, cholesterol disposal, and the inflammatory re-
sponse, and promotes changes in the cellular and
extracellular composition of the artery wall that may im-
pact on the response to injury and atherosclerosis. HIF
and its down-stream effector gene products have been
increasingly recognized for their key role in regulating a
wide-spectrum of cellular events, including angiogenesis,
cell proliferation, apoptosis and protective response to
limit tissue damage (Imtiyaz and Simon 2010; Walshe
and D'Amore 2008). There is also increasing evidence
that HIF-1α plays a critical role in an early cardioprotec-
tive response (Ke and Costa 2006; Tekin et al. 2010),
whilst HIF-2α mediates a delayed cardio protective ef-
fect, playing an important role in adapting the cells to
chronic hypoxia and injury (Bautista et al. 2009; Ong
and Hausenloy 2012). Therefore measurement of HIF-
1α rather than HIF-2α may be useful for the assessment
of acute disease severity and prognosis.
The measurement of HIF-1α in plasma and cells
Although HIF-1α is known to be unstable, there have
been previous reports of the measurement of HIF-1α in
plasma in man and in rats (He et al. 2016b; Li et al. 2015;
Xu et al. 2016). However the description of the sample
collection and storage procedures are poorly reported in
these studies. In this current paper we have confirmed
that HIF-1α is indeed unstable, and that careful collection
procedures are essential to prevent its degradation. We
found that blood samples and cell lysates can be stored for
up to two weeks at -80 °C in the presence of protease in-
hibitors. Whilst we used aprotinin at a final concentration
of 300 nM, we found that other protease inhibitors such
Fig. 6 Induction of plasma HIF-1α (a) and VEGF gene expression in the carotid artery tissue (b) after local application of DMOG (0–7.5 mg/Kg) as
arbitrary units versus the uninjured samples. Data are the mean ± SEM (n = 6), *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 5 Time course of the levels of intracellular HIF-1α (a) and VEGF mRNA (b) after a scratch assay in vitro. HIF-1α was measured by ELISA and
VEGF mRNA by qPCR. HIF-1α levels are expressed as pg/mg protein and VEGF mRNA levels as arbitrary units versus the uninjured samples. Data
are the mean ± SEM of 6 samples. *P < 0.05, P** < 0.01 and ***P < 0.001
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Fig. 7 a Increase in plasma HIF-1α in a rat angioplasty model. Plasma levels of HIF-1α, measured by ELISA, increased after injury, reaching a maximum
after 48 h. (b) VEGF mRNA levels in the injured carotid and the contralateral carotid of the same rats as arbitrary units versus the uninjured samples.
Data are mean ± SEM (n = 6). *P < 0.05, ** P < 0.01 and *** P < 0.001
Fig. 8 Panel I represents immunohistochemistry of (a) untreated carotid arteries and injured carotid arteries (b) immediately after injury (c)
2 days post injury and (d) 5 days post injury using a Leica CTR 5000 fluorescence microscope. Arteries were stained with mouse anti-HIF-1α
and followed by FITC-conjugated anti-mouse secondary antibody (green stain) to visualize HIF-1α. Nuclei were stained with DAPI (Blue stain).
1 represents the lumen, 2 represents the smooth muscle cells and 3 represents the Tunica adventitia. Images shown are at 40× magnification
and 63× magnification (inset images). Red arrows indicate the localization of HIF-1α expression in the smooth muscle cells. Panel II represents
the staining of endothelial cells (EC) and smooth muscle cells (SMCs). The yellow arrow indicates EC layer in control (uninjured) arteries which
is removed post injury and starts to regenerate 5 days post injury. Arteries were stained with rabbit anti-CD31 and mouse anti-alpha smooth
muscle actin followed by Alexafluor 647 conjugated anti-rabbit secondary antibody (red stain) and FITC-conjugated anti-mouse secondary
antibody (green stain) to visualize EC and SMCs respectively
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as Complete Mini protease inhibitor cocktail tablets
(Roche) have a similar effect (data not shown).
The HIF-1α ELISA was robust, of adequate sensitivity
and precision for use in biological samples. The values ob-
tained using the ELISA were consistent with Western blot
analysis using different HIF-1α antibodies. The measure-
ment of HIF-1α in the in vitro studies was also consistent
with expectations: hypoxia and a known HIF-1α inducer
increased intracellular HIF-1α levels and down-stream
VEGF expression. HIF-1α is involved in regulating the
expression of VEGF, which is one of the most potent
proangiogenic growth factors (Song et al. 2017). The ex-
pression of VEGF was measured to confirm that the levels
of HIF-1α in the biological samples were sufficient to
cause down-stream signalling.
We observed that there was a transient increase in
the expression of HIF-1α and VEGF in a model of rat
aortic endothelial cell (RAECs) injury in vitro. The
rapid increase in HIF-1α levels from injured RAECs
reached a peak level at approximately 2 h post injury
in the scratch model. This occurred under normoxic
conditions and in the absence of inflammatory cells
showing that HIF-1α is directly involved in the adap-
tive response to cell injury.
HIF-1α and vascular injury
vIn vivo, DMOG, applied locally to a rat carotid artery,
caused a systemic increase in plasma HIF-1α that peaked
at 2 days, and was approximately 3-fold higher than
baseline values. This was associated with an up-
regulation of the local, but not the contralateral VEGF
arterial tissue expression. HIF-1α appears to be an im-
portant mediator of the pro-atherogenic cellular re-
sponse to hypoxia and is up-regulated in inflammatory
and hypoxic areas of carotid arteries in simple and com-
plex lesions from patients with carotid artery disease. In
vascular smooth muscle cells, HIF-1α can be activated
under normoxic conditions by platelet products such as
platelet derived growth factor and thrombin (Gorlach et
al. 2001). In the rat carotid balloon injury model, plate-
lets are deposited on the injured artery within minutes
of injury, and that they are important in the subsequent
formation of the neo-intima (Fingerle et al. 1989). In a
murine model of vascular injury, HIF-1α expression was
shown to be increased in the smooth muscle cells of the
tunica media, as early as 1 day after injury, HIF-1α
mRNA expression was induced at 6 h after injury, and
its inhibition by the local application of HIF-1α -siRNA
reduced neo-intimal area by 49% and significantly de-
creased the neo-intimal smooth muscle cells content.
HIF-1α expression therefore appears to be directly in-
volved in the formation of the neo-intima after vascular
injury (Karshovska et al. 2007).
Conclusions
It is possible to measure HIF-1α in biological samples
using an ELISA assay, although careful sample preparation
and storage is essential. This may be of value in conditions
in which tissue hypoxia may play a role, including cancer,
cardiovascular disease and pulmonary disease.
HIF-1α is rapidly up-regulated in an in vitro, wound-
healing model, the scratch assay, even in the absence of
hypoxia. It is therefore likely to play an important role in
orchestrating the response to injury.
The up-regulation of HIF-1α expression and release was
more sustained in the rat balloon injury model, where
plasma HIF-1α reached its peak concentrations 2 days
post injury. The differences in the kinetics of HIF-1α ex-
pression and release for the in vitro and in vivo models
could be due to the complexity of the in vivo model. The
latter model involves several cell types, including VSMS,
platelets and inflammatory cells; these may interact to
stimulate pathways that could lead to a more sustained
HIF release that may have implications for conditions
such as coronary atherosclerosis, restenosis and stroke.
Additional file
Additional file 1: Figure S1. Effect of adding the protease inhibitor;
aprotinin on HIF-1α levels in plasma when added directly to the blood
after collection versus addition to the plasma after separation. Blood was
spiked with HIF-1α protein (0.6 ng/mL). Blood samples were then split
into two groups where the protease inhibitor was added to one
group after which plasma was separated. In the other group, plasma
was separated first prior to the addition of protease inhibitor. Data
represented are the mean ± SEM of 3 rats (triplicate of each). (DOCX
23 kb)
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